Cambridge Investment Research Advisors Increases Stake in Zoetis with 1656 Share Acquisition
December 29, 2022
Trending News ☀️
Zoetis Inc ($NYSE:ZTS). is a leading animal health company dedicated to supporting customers and their businesses in ever better ways. It offers a range of innovative products and services to veterinarians, livestock producers, and other animal care providers, such as vaccines and medicines, diagnostic products, genetic tests, and biodevices. Zoetis is also dedicated to developing a diverse pipeline of new products and services that will enhance the well-being of animals and the people who care for them. Cambridge Investment Research Advisors Inc. recently announced that it has acquired 1656 shares of Zoetis Inc. This demonstrates the firm’s commitment to further investing in the animal health industry. The purchase also bolsters the firm’s portfolio of investments in the healthcare sector, which includes pharmaceuticals, medical technology, and biotechnology companies. By adding to its stake in Zoetis Inc., Cambridge Investment Research Advisors Inc. is showing its confidence in the company’s potential for growth. The company has a long history of creating innovative solutions that address the needs of its customers.
Additionally, Zoetis has a strong research and development program that is focused on creating new products and services that can improve animal health and welfare. This purchase is an important step for Cambridge Investment Research Advisors Inc., as it shows their confidence in the future of Zoetis Inc. The company’s commitment to investing in the animal health industry demonstrates their belief that this sector has tremendous potential for growth and will continue to be a strong source of returns for their investors.
Market Price
The move comes despite the fact that the media exposure of Zoetis Inc. has been mostly positive till now. On Tuesday, the stock of Zoetis Inc. opened at $145.9 and closed at $145.3, down by 0.3% from its previous closing price of 145.8. This acquisition by Cambridge Investment Research Advisors Inc. indicates an increase in their confidence in the potential of Zoetis Inc. It also shows that they are willing to invest more in the company’s future growth. This move could be seen as a vote of confidence in the company and its ability to deliver good returns to its investors in the near future.
The acquisition of 1656 shares is a relatively small number, but it could be seen as a signal for larger investments in the future. It is also possible that Cambridge Investment Research Advisors Inc. is expecting a positive response from the market and is looking to capitalize on it. This could lead to an increase in the stock price and a better outlook for the company’s future prospects. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Zoetis Inc. More…
| Total Revenues | Net Income | Net Margin |
| 8.01k | 2.07k | 26.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Zoetis Inc. More…
| Operations | Investing | Financing |
| 1.85k | -587 | -2k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Zoetis Inc. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 13.67k | 9.01k | 10 |
Key Ratios Snapshot
Some of the financial key ratios for Zoetis Inc are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 9.2% | 13.2% | 34.8% |
| FCF Margin | ROE | ROA |
| 15.8% | 37.6% | 12.7% |
VI Analysis
ZOETIS INC is a company with potential for long-term growth. According to the VI Risk Rating, ZOETIS INC is a medium-risk investment which takes into account financial and business aspects. Although this may be a riskier venture than some other investments, the company has potential for growth as indicated by its fundamentals. The VI App has identified one risk warning in the balance sheet of ZOETIS INC. On the app, investors can access this information and use it to make an educated decision on whether or not to invest in the company. By registering on the VI App, investors can also gain access to additional data which can help them understand their risks and potential rewards when investing in this company. Overall, ZOETIS INC may be a riskier investment than some other options, but it also possesses potential for growth and reward. With the help of the VI App, investors can make an informed decision on whether or not to invest in the company based on its fundamentals and the risk warnings present in its balance sheet. More…
VI Peers
Zoetis Inc. is a global animal health company that develops, manufactures, and markets a wide range of veterinary products. The company’s products include vaccines, parasiticides, pharmaceuticals, diagnostics, and biologics. Zoetis Inc. has a broad portfolio of products that are used in the prevention, treatment, and control of disease in animals. The company’s competitors include BioGaia AB, Krka d.d., and Phibro Animal Health Corp.
– BioGaia AB ($OTCPK:BIOGY)
Biogaia is a Swedish biotech company that markets probiotic products for infants, children, and adults. The company’s products are based on the lactic acid bacterium Lactobacillus reuteri, which is found naturally in the human gastrointestinal tract. Biogaia’s products are sold in over 60 countries worldwide.
Biogaia’s market cap is 800.05M as of 2022. The company has a Return on Equity of 10.86%. Biogaia’s products are based on the lactic acid bacterium Lactobacillus reuteri, which is found naturally in the human gastrointestinal tract. Biogaia’s products are sold in over 60 countries worldwide.
– Krka d.d. ($LTS:0HLK)
Krka d.d. is a Slovenian pharmaceutical company. It is the largest pharmaceutical company in Slovenia and one of the largest in the Balkans. The company was founded in 1959 and is headquartered in Novo mesto. Krka d.d. has a market cap of 2.77B as of 2022 and a Return on Equity of 12.85%. The company’s main products are prescription drugs, over-the-counter drugs, and medical devices.
– Phibro Animal Health Corp ($NASDAQ:PAHC)
Phibro Animal Health Corporation is a diversified animal health and specialty ingredients company with products in over 100 countries. The company’s products are sold through veterinarians, distributors, and feed stores. Phibro Animal Health Corporation’s mission is to improve the health and productivity of animals. The company’s products are used in a variety of animals, including cattle, swine, poultry, and aquaculture. Phibro Animal Health Corporation’s products are designed to improve the health and productivity of animals while providing a safe and healthy environment for them to live in.
Summary
Zoetis Inc. is a global animal health company that develops, manufactures, and commercializes medicines and vaccines for both livestock and companion animals. Recently, Cambridge Investment Research Advisors Inc. increased its stake in Zoetis Inc. by acquiring 1656 shares. So far, the media has provided mostly positive coverage of the company’s investments.
It appears that the company’s products have been successful, as it continues to create innovative solutions for animal health that are safe and cost effective. Zoetis Inc. is committed to providing the best possible care for animals, and this commitment is reflected in its investments and success.
Related Posts
Recent Posts
